Aligos Therapeutics Inc Dossier - Source-backed chat

Aligos Therapeutics Inc

ALGSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.87

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $5.63Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $35.2M

Enterprise Value $4.8M

Shares Outstanding 6.2M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Aligos Therapeutics is a high-potential, clinical-stage biopharmaceutical company advancing a robust pipeline targeting chronic hepatitis B virus (HBV) and metabolic dysfunction-associated steatohepatitis (MASH). The investment thesis is anchored on the potential best-in-class profile of its lead assets: pevifoscorvir sodium (a capsid assembly modulator in Phase 2) and ALG-055009 (a THR-β agonist in Phase 2a). While the company is pre-revenue and faces a near-term capital runway constraint extending only into Q4 2026, its scientific validation is strong, highlighted by ten accepted abstracts at the EASL Congress 2026 and a lucrative Greater China licensing deal with Amoytop. Successful clinical readouts in late 2026 and 2027 serve as major valuation catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$56.29

High · most bullish analyst$175.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.0015%

In the bear case, the Phase 2 B-SUPREME trial experiences enrollment delays or fails to show a statistically significant treatment effect at the primary endpoint despite the sample size expansion. Additionally, ALG-055009's Phase 2a MASH data fails to differentiate from established competitors, or safety concerns emerge. Capital markets remain tight, forcing highly dilutive financing or program prioritization that curtails the broader pipeline.

Base CaseCentral scenario

$38.5060%

The base case assumes steady execution of the Phase 2 B-SUPREME trial with the expanded sample size, keeping the program on track for a 2027 topline readout. ALG-055009 meets its primary endpoints in the Phase 2a MASH trial in H2 2026, confirming competitive efficacy and safety. To address the Q4 2026 cash runway limit, the company successfully secures additional capital through a combination of secondary equity offerings, non-dilutive grant funding, or regional licensing partnerships.

Bull CaseUpside scenario

$70.0025%

In the bull case, pevifoscorvir sodium demonstrates superior, sustained reductions in HBV antigens during its Phase 2 B-SUPREME trial, positioning it as a cornerstone of a functional cure regimen. Simultaneously, ALG-055009 delivers outstanding Phase 2a MASH data in H2 2026, showing superior liver fat reduction and lipid profiles compared to existing THR-β therapies. This clinical success triggers a high-value global pharmaceutical partnership or acquisition, completely resolving cash runway concerns and driving substantial valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pevifoscorvir sodium holds FDA Fast Track Designation and has demonstrated best-in-class reductions in HBV DNA, RNA, and antigens in clinical studies.
Strong scientific validation with ten abstracts accepted at the prestigious EASL Congress 2026.
Strategic regional partnership with Amoytop for Greater China provides upfront cash ($25M) and validates the commercial potential of the HBV program.
ALG-055009 is designed as a highly potent and selective THR-β agonist, targeting a multi-billion dollar MASH and obesity market.

Key Investment Risks

Limited cash runway extending only into Q4 2026, requiring near-term dilutive or non-dilutive financing.
Clinical development risk, as demonstrated by the DSMB's recommendation to increase the B-SUPREME sample size to optimize statistical power.
Intense competition in both the HBV functional cure and MASH/obesity therapeutic landscapes.

Thesis Invalidation Triggers

Failure of pevifoscorvir sodium to meet primary endpoints in the Phase 2 B-SUPREME trial.
Inability to secure additional financing or strategic partnerships before the cash runway expires in Q4 2026.
Unfavorable safety signals or lack of efficacy differentiation for ALG-055009 in the H2 2026 Phase 2a MASH readout.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.